As the importance and prevalence of oligonucleotide therapeutics continue to grow, so does the need for robust characterization methodologies throughout drug development and production.
Given the intricate relationship between structure and therapeutic efficacy in this drug class, detailed structural characterization is essential. Nuclear Magnetic Resonance (NMR) provides comprehensive structural insights across the spectrum of oligonucleotide-based therapies in development. This webinar will explore the latest advancements in NMR-based characterization of oligonucleotide therapeutics.
Presentations
- The vital role of NMR in analyzing nucleic acids’ structure and dynamics for small molecule drug discovery advancements: Celestine Chi, AstraZeneca
- Multi-attribute assessment of anti-sense therapeutics: Robert Brinson, IBBR, NIST
- NMR of RNA and therapeutic oligonucleotides: Martial Piotto, Bruker BioSpin
Key learning topics
- NMR approaches for oligonucleotide characterization
- Pharmaceutical trends and requirements for oligonucleotide-based therapies
- Bruker's latest developments for oligonucleotide and macromolecular therapeutic characterization.
About the speakers
Dr. Celestine Chi is a famous researcher who specializes in molecular sciences. He earned his Ph.D. at Uppsala University in Sweden under Prof. Per Jemth, researching carefully into the complexities of protein folding and binding. Dr. Chi then worked as a postdoctoral researcher at ETH Zurich under Prof. Roland Riek.
He later returned to Uppsala University before entering the industry. Dr. Chi is currently an NMR specialist and Senior Scientist at AstraZeneca in Gothenburg, Sweden, where he is working to unlock the enigmatic world of non-coding genomes, unravel structural dynamics, and pioneer novel methodologies for precisely targeting these entities with small molecules.
Robert Brinson uses biophysical techniques to characterize the structure and dynamics of nucleic acids, proteins, and glycoproteins. Brinson intends to push the boundaries of NMR methods to determine the important qualitative attribute of higher-order structure in medicinal compounds.
He earned his Ph.D. in chemistry from Wake Forest University before moving on to structural biology as an NIH/NIST NRC postdoctoral scholar under John Marino (NIST) and Stuart Le Grice (NCI). Under their supervision, Brinson conducted high-resolution NMR research on key nucleic acid components from diverse viruses.
Martial Piotto received his Ph.D. in NMR spectroscopy from the University of Purdue, US (Pr. D. Gorenstein). He later joined Bruker France as head of NMR application, where he worked on a variety of NMR spectroscopy projects, including the development of new pulse sequences and HRMAS technology.
Over time, he became interested in NMR applications in the pharmaceutical and medical fields. His present study focuses on the characterization of biologics (mAbs, vaccines, and therapeutic oligonucleotides) using NMR and multivariate statistical methods.